At a glance
ClinicalIndex Comparison RecordN/ACompleted· 127 enrolled
Drug / intervention
Artificial Pancreas +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-Augmented Pump Therapy in the Management of Type 1 Diabetes
In Brief
A clinical study evaluating Artificial Pancreas and Sensor Augmented Therapy for Type1 Diabetes Mellitus. Completed, enrolled 127 participants across 7 sites.
Detailed Summary
The objective of the study is to assess the efficacy and safety of home use of a Control-to-Range (CTR) closed-loop (CL) system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType1 Diabetes Mellitus
CountriesUnited States
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartOct 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedDec 7, 2016
Enrollment StartOct 27, 2017
Primary CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.6 years ago
Interventions
Artificial Pancreasdevice
Use of CTR at home for 3 months
Sensor Augmented Therapyother
Use of personal pump with study CGM \& glucometer at home for 3 months